Latest Headlines
-
Dr. Reddy's Launches Novel Molecule 'Tegoprazan' In India
9/16/2025
Dr. Reddy’s Laboratories Ltd. (along with its subsidiaries together referred to as “Dr. Reddy’s”), announced the launch of the novel molecule ‘Tegoprazan’, for acid-related gastrointestinal diseases in India. Dr. Reddy’s launches Tegoprazan (50 mg) under the brand name PCAB.
-
New Drug Lowers Treatment-Resistant High Blood Pressure And May Slow Kidney Disease
9/16/2025
A new drug has shown unprecedented promise in lowering blood pressure and preventing the progression of kidney disease for people with hard-to-treat hypertension. The medication, baxdrostat, reduces the levels of a hormone that drives high blood pressure and could transform hypertension care.
-
New AI Molecular Prediction Model Could Speed Up Drug Discovery
9/15/2025
Innovative research conducted in collaboration between a graduate student here and the global biopharmaceutical leader AstraZeneca has led to an important advancement in the field of AI-assisted drug discovery.
-
Mycenax And SPERA PHARMA Forge Strategic Alliance To Streamline ADC Drug Substance And Drug Product Manufacturing Services
9/15/2025
Mycenax Biotech Inc. (TWO:4726), a leading biologics CDMO based in Taiwan, today announced strategic alliance with SPERA PHARMA Inc., a Japan-based expert in pharmaceutical Chemistry, Manufacturing, and Controls (CMC).
-
Queen Mary Trials New Approach To Drug Development For Rare Diseases
9/11/2025
Developing disease modifying therapies for rare diseases is extremely challenging. It’s clinically difficult due to the small cohort sizes, and it’s difficult to raise investment as the market may not be big enough to cover the costs.
-
GNQ Insilico Launches Revolutionary AI-Driven Assessment Platform To Transform Precision Medicine And Drug Development
9/11/2025
GNQ Insilico Inc. (“GNQ” or “the Company”), a pioneering TechBio firm leveraging exponential technologies for precision medicine, announces the official launch of its groundbreaking deep tech Drug Assessment Platform (DAP).
-
Absci Accelerates AI-Driven Drug Discovery With Oracle And AMD
9/11/2025
Absci, a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to accelerate generative AI-driven drug discovery.
-
FDA Files Corcept's New Drug Application For Relacorilant As A Treatment For Patients With Platinum-Resistant Ovarian Cancer
9/10/2025
Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA) has accepted Corcept’s New Drug Application (NDA) for relacorilant as a treatment for patients with platinum-resistant ovarian cancer
-
Symeres Acquires DGr Pharma To Enhance Regulatory Expertise And Broaden Its Biopharma Capabilities
9/10/2025
Symeres, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announces the acquisition of DGr Pharma, a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients.
-
Lilly Launches TuneLab Platform To Give Biotechnology Companies Access To AI-Enabled Drug Discovery Models Built Through Over $1B In Research Investment
9/9/2025
Eli Lilly and Company (NYSE: LLY) today announced the launch of Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that provides biotech companies access to drug discovery models trained on years of Lilly's research data.